The American Urological Association, the Society of Urologic Oncology and the European Association of Urology have recently updated their guidelines for diagnosis and treatment of non-muscle-invasive bladder cancer. Several studies show that adherence to these guidelines is low, especially in North America. Physicians should try to comply with these guidelines to ensure optimal quality of care.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
De behandeling van blaaskanker vraagt om gecentraliseerde zorg
Tijdschrift voor Urologie Open Access 12 September 2017
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Chang, S. S. et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline. J. Urol. http://dx.doi.org/10.1016/j.juro.2016.06.049 (2016).
Babjuk, M. et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur. Urol. http://dx.doi.org/10.1016/j.eururo.2016.05.041 (2016).
Witjes, J. A. et al. Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guérin (BCG): results of an international individual patient data survey (IPDS). BJU Int. 112, 742–750 (2013).
Gontero, P. et al. Are referral centers for non-muscle-invasive bladder cancer compliant to EAU guidelines? A report from the vesical antiblastic therapy Italian study. Urol. Int. 86, 19–24 (2011).
Reek, C. et al. Quality of care in patients with newly diagnosed bladder cancer: a prospective assessment in northern Germany. Urologe A 52, 986–990 (2013).
Siddins, M. T., Wong, V. V., Fitzgerald, J. T. & Bamberg, L. J. Challenges in non-muscle invasive bladder cancer: lessons from a regional review. ANZ J. Surg. 81, 889–894 (2011).
Madeb, R. et al. Treatment of non-muscle invading bladder cancer: do physicians in the United States practice evidence based medicine? The use and economic implications of intravesical chemotherapy after transurethral resection of bladder tumors. Cancer 115, 2660–2670 (2009).
Gotto, G. T., Shea-Budgell, M. A. & Dean Ruether, J. Low compliance with guidelines for re-staging in high-grade T1 bladder cancer and the potential impact on patient outcomes in the province of Alberta. Can. Urol. Assoc. J. 10, 33–38 (2016).
Huang, G. J., Hamilton, A. S., Lo, M., Stein, J. P. & Penson, D. F. Predictors of intravesical therapy for non-muscle invasive bladder cancer: results from the surveillance, epidemiology and end results program 2003 patterns of care project. J. Urol. 180, 520–524 (2008).
Chamie, K. et al. Compliance with guidelines for patients with bladder cancer: variation in the delivery of care. Cancer 117, 5392–5401 (2011).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
PowerPoint slides
Rights and permissions
About this article
Cite this article
van Rhijn, B., Burger, M. Low adherence to guidelines in non-muscle-invasive disease. Nat Rev Urol 13, 570–571 (2016). https://doi.org/10.1038/nrurol.2016.165
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2016.165
This article is cited by
-
Attention to detail and a permissive set-up: crucial for an effective TURBT
Nature Reviews Urology (2021)
-
Prognostic impact of non-adherence to follow-up cystoscopy in non-muscle-invasive bladder cancer (NMIBC)
World Journal of Urology (2019)
-
De behandeling van blaaskanker vraagt om gecentraliseerde zorg
Tijdschrift voor Urologie (2017)